Abstract | The primary goal of nanomedicine is to improve clinical outcomes. To this end, targeted nanoparticles are engineered to reduce non-productive distribution while improving diagnostic and therapeutic efficacy. Paradoxically, as this field has matured, the notion of targeting has been minimized to the concept of increasing the affinity of a nanoparticle for its target. This Opinion article outlines a holistic view of nanoparticle targeting, in which the route of administration, molecular characteristics and temporal control of the nanoparticles are potential design variables that must be considered simultaneously. This comprehensive vision for nanoparticle targeting will facilitate the integration of nanomedicines into clinical practice.
The central promise of targeted drug delivery technologies is improved efficacy by increasing the drug concentration at a desired (or target) site while simultaneously minimizing toxicity by reducing off-target accumulation. The past several years have seen the development of an enormous array of systems engineered to fulfil this drug targeting promise. Such systems range from the conjugation of a hydrophilic polymer to a hydrophobic drug 1 to more complex nanocarrier systems that can dynamically respond to local environmental cues 2 . Ultimately, the utility of any drug delivery system -regardless of the materials used or mechanism of action -should be judged with respect to the aforementioned criteria; that is, the targeting system significantly improves efficacy and reduces toxicity by providing control over the drug biodistribution and pharmacokinetics. Many current approaches for targeted drug delivery systems assume that the best mechanism for controlling the fate of a therapeutic agent is by hijacking cellular receptor-ligand interactions. Often, less consideration is given to other factors that can dramatically affect the ability to control the delivery of a drug to a specific site. These other factors include the route of administration, the surface adsorption of serum proteins, drug release kinetics and biological timing. To realize the full potential of targeted drug delivery, we believe that targeting should be more comprehensively defined to also include these non-canonical aspects. A holistic view of targeting covers all aspects of delivery from the macroscale (for example, where and how the therapeutic is introduced into the body) to the microscale (for example, the molecular interactions that govern how a delivery system interacts with cells and the extracellular milieu) (FIG. 1) .
More than any other class of drug delivery vehicle, polymer-based nanoparticles have the capacity to fully realize this holistic view of targeting. Polymeric nanoparticles (with a diameter of <300 nm) are structurally defined as solid nanoparticles, micelles, polyplexes or dendrimers
. These colloidal polymeric systems have gained considerable commercial and translational attention mostly owing to their improved stability, biocompatibility and potential for extended drug release kinetics compared with non-polymeric nanosystems 3 . In addition, polymeric nanoparticles provide versatility through the use of polymers of different chemical composition, hydrophilic-lipophilic balance, charge and physical structure, among other properties. As a result of this versatility, nanoparticles can be formulated to deliver a range of drugs and should be adaptable to many clinical settings. Moreover, the ability to control the degradation or disassembly of polymeric nanoparticles imparts the ability to control temporal aspects of drug delivery across a wider range than permitted by other forms of nanoparticles. This diversity of potential applications renders polymeric nanoparticles attractive as therapeutic delivery vehicles. However, for each new nanoparticle formulation, this diversity must be matched with a comprehensive understanding of how both the biology of the target disease and the properties of a nanoparticle therapeutic influence delivery.
As the field of nanoparticle delivery matures (TABLE 1) , so must the principles guiding further innovation. Adopting a holistic view -that includes all aspects of nanocarrier design and deployment as inter-related tools to mediate targetingwill facilitate the clinical translation of technologies and treatment paradigms. This integrated view may also shift the focus away from the development of complex nano particle formulations -which are likely to be difficult to scale up for commercial availability -and towards simple, judiciously constructed solutions that are more likely to find clinical success. In this Opinion article, we present a new outlook on targeting polymeric nanoparticles for drug delivery, which we divide into anatomical, molecular and temporal aspects (FIG. 1) . Although our primary focus is on polymeric nanoparticles, other drug delivery platforms, such as liposomes, are often used under similar circumstances and therefore face many of the same challenges as polymeric nanoparticles. As such, our conclusions present a broad perspective on targeting that will have an impact on the design of all types of nanotherapeutics.
Current state-of-the-art
The majority of currently used targeted nanoparticles are engineered to treat cancer by intravenous administration (TABLE 1) , and the details of such nanoparticles have been Nature Reviews | Drug Discovery N a t i v e l i g a n d covered in several recent reviews [4] [5] [6] . Previous generations of tumour-targeted nano particles were designed to maximize passive targeting, in which systemically circulating nanoparticles penetrate the leaky vasculature that is often associated with tumours and accumulate owing to slow clearance because of poor lymphatic drainage. This type of passive targeting is called the enhanced permeability and retention (EPR) effect. Nanoparticles with a diameter of approximately 100 nm seem to be optimal for taking advantage of the EPR effect to target many types of tumours 7 . In the passive targeting approach, increasing the accumulation of nanoparticles at the tumour correlates with longer circulation times; therefore, the surface of these particles is often coated with inert materials (such as polyethylene glycol (PEG)) to reduce protein opsonization and phagocytic elimination, prolonging circulation time and subsequently enhancing accumulation in tumours. To further improve on passive targeting, many of the current generation of nanoparticles rely on the promise of molecular (or active) targeting enhancements. In active targeting, the surface of nanoparticles is coated with molecules (for example, native ligands or antibodies) that can, in theory, increase the affinity of the nanoparticles for specific cells or tissues, and potentially facilitate receptormediated uptake. Often, active targeting is used in combination with nanoparticle formulations that are designed to enhance passive targeting. Two examples of such polymeric nanoparticle systems currently in clinical trials are BIND-014 and CALAA-01 (REFS 8, 9) . These two formulations are surface-modified with both PEG and targeting molecules that bind to receptors that are enriched on some cancer cells 8, 9 . Although it is not the primary focus of this article, it is worth noting that there have also been some promising advances in the targeting of free drugs, such as the chemical stabilization of oligonucleotides 10 and ligand-oligonucleotide conjugates 11 . Despite much attention on molecular approaches to targeting, the results have been mixed. Although there have been some intriguing successes, current technologies for ligand-receptor targeting of nanoparticles do not produce predictable outcomes 12, 13 . Indeed, there is growing evidence indicating that the presence of targeting ligands can have a negative influence on passive targeting by reducing circulation times through enhanced immune elimination 6, 13 . In addition, the assumption that the specificity of a targeting ligand will be retained after conjugation to a nanoparticle surface is flawed, particularly when the nanoparticles are delivered in vivo 12 . Furthermore, even if a highly specific targeted nanoparticle can be achieved, there is no guarantee that a unique receptor will be substantially expressed solely on the cell population of interest. These challenges have raised questions regarding whether the added complexity that comes with the introduction of active targeting ligands is of value, particularly as complex nano particle delivery systems are both difficult and expensive to develop for clinical use 14 . Thus, despite the potential arising from recent innovations in nanoparticle synthesis, it is unclear how much closer these innovations have led the field to fulfilling the promise of drug targeting and where exactly the field should now focus its attention.
We believe that a more nuanced view of targeting will facilitate the design of clinically useful systems to better deliver on the potential of nanoparticle drug delivery. A typical approach for designing targeted therapies focuses first on the development of a drug delivery platform, which is then screened against a variety of diseases to find the setting in which the greatest efficacy can be achieved. We prefer a top-down strategy in which a given disease indication fuels the design of nanomedicines. Recently, others have expressed a similar approach that begins by selecting a particular disease and then sampling relevant drug delivery platforms to identify the best method for treating that pathology 15 . Such an approach focuses attention on the biological characteristics that define a given disease, and how nanoparticles are likely to interact with cells and tissues in that context. Thus, the emphasis is on designing a targeting system that is specifically tailored to these characteristics.
In addition to first considering the disease state, we argue that it is also essential to broaden the focus of nanoparticle delivery beyond the current emphasis on active targeting by intravenous delivery. For many diseases, alternative routes of administration may be more effective than systemic delivery. Furthermore, regardless of whether targeting molecules are utilized or not, it is crucial to consider how the physicochemical properties of the nanoparticle and the surrounding biological milieu affect the ability to target at the molecular level. Finally, there are also important temporal aspects to targeting, including the relationship between pharmacokinetics, drug release kinetics and the therapeutic window for effective disease treatment. In the following sections, we expand on this more comprehensive notion of targeting by providing examples of how a holistic approach can better fulfil the promise of targeted nanomedicines.
Anatomical targeting
Targeting implies a direct focus on one object of interest while simultaneously ignoring everything else. For nanoparticles that are intended to target a single population of cells, this concept is difficult to translate into practice, particularly when the particles are administered systemically. Although delivery to the blood circulation has the potential benefit of providing access to any vascularized tissue in the body, this pervasive access also increases the likelihood that unintended tissues will be targeted. It is typically observed that systemic delivery of nanoparticles results in substantial accumulation in both the liver and the spleen This figure provides a representation of the key factors that influence nanoparticle targeting, which is organized into anatomical routes of delivery, and molecular and temporal aspects. The outer wheel highlights some approaches in which nanoparticles can be targeted within the three subgroups. First, different anatomical routes of delivery will affect particle biodistribution, which provides an initial level of targeting. Second, molecular modifications, either in the form of chemically conjugated targeting ligands and/or proteins adsorbed from the local environment, have the ability to modulate the nature of the cellular interactions. Third, the choice of when to treat a disease (biological timing), combined with engineering nanoparticles to have defined drug release profiles (nanoparticle timing), provides an additional mechanism of targeting. The design of targeted nanoparticles must be holistic and consider all aspects simultaneously, as the three areas are interconnected -that is, any choice made in one aspect of delivery will have substantial effects on the other areas. CNS, central nervous system. as a result of immune clearance by the mononuclear phagocyte system (also known as the reticuloendothelial system) 16 . Unless these phagocytic cells of the liver (or spleen) are the intended target, this off-target accumulation is a major impediment to achieving specificity with systemic delivery.
Alternatively, the directed local delivery of drugs is a simpler and (for some diseases) potentially more effective form of targeting that enables a physical means of enriching nanoparticles at a specific site and reducing accumulation in non-target tissues [17] [18] [19] [20] . Local delivery has been shown to be useful in treating brain tumours; implantation of a macroscopic polymer wafer provided sustained effective concentrations of a chemotherapy drug in the brain while sparing other tissues from drug exposure 21 . Local administration can also be achieved with nanoparticles through a range of physical and minimally invasive targeting methods that are appropriate for specific diseases (TABLE 2) . The following examples provide a sampling of how local modes of nanoparticle administration can be used as a means to enhance disease targeting.
Brain infusion. The most basic method for targeting by local administration of nanoparticles is direct injection into the tissue of interest. Such injections are invasive but, in some cases, physiological barriers substantially impair the effectiveness of any other delivery route. The blood-brain barrier (BBB) is one such physiological impediment; despite decades of effort, no systemically targeted nanoparticle system provides adequate transport across the BBB to enable effective treatment of serious brain diseases, such as glioblastoma multiforme 17, [22] [23] [24] [25] . Alternatively, nanoparticles can be directly injected into the brain (thereby circumventing the BBB) using catheters that are stereotactically targeted to precise anatomical locations. Moreover, approaches such as convection-enhanced delivery can be used to target larger volumes of the brain to ensure that the injected particles fully cover the targeted area 22, 26, 27 . Nanoparticles are potentially useful in this setting because they enable sustained intracellular delivery of the encapsulated agent, which is a crucial feature when repeat dosing is not practical. In addition, effective delivery relies on the ability of nanoparticles to penetrate away from the site of injection and into proximal surrounding diseased tissue. For convection-enhanced delivery, nanoparticle size seems to be the primary property that influences susceptibility to convective transport within the brain; for example, atypically small poly(lactic-co-glycolic acid) (PLGA) nanoparticles can be transported over large distances from the site of infusion by convection 23 . The invasiveness of this delivery method will limit its broad application, but it is potentially useful for the delivery of agents that reverse Parkinson's disease 28 or Huntington's disease 29 . In addition, this approach can be extended to other parts of the nervous system, as demonstrated by the injection of protein growth factor-loaded nanoparticles to treat spinal cord injury 30 or the injection of various nanoparticles into the eye to treat retinal diseases 31, 32 .
Dermal administration. Direct local administration to target nanoparticles need not be as invasive as delivery to the brain. For example, topical application to the skin is non-invasive and yet still provides physical targeting. As evidence of the safety of this approach, chitosan, PLGA, poly(DL-lactide) (PLA), polyalkylcyanoacrylate and polycaprolactone polymers are routinely used in dermal delivery for both therapeutic and cosmetic purposes 18 . Generally, topically applied nanoparticles are unable to penetrate deeply into the stratum corneum (the outermost layer of the epidermis) and instead localize to proximal glands and hair follicles 33 . As such, topically applied nanoparticles typically cannot reach subepithelial capillaries to access the circulatory system. Nevertheless, particles can be formulated to penetrate deep enough to have substantial therapeutic benefits. For example, PLGA nanoparticles coated with a cationic lipid that induced swelling and opening of the stratum corneum were used to co-deliver capsaicin (an antiinflammatory drug) and small interfering RNA (siRNA) against tumour necrosis factor (TNF) to treat the chronic inflammation of psoriasis 18 . Importantly, this strategy has the potential to avoid the widespread immunosuppressive side effects that are associated with systemic delivery of TNF antagonists 34 . The limited spread to surrounding tissues observed in dermal delivery provides a substantial safety benefit. In addition to this spatial advantage, the local retention of topically applied therapeutics imparts a temporal advantage by increasing treatment duration. Both brain infusion and topical skin administration demonstrate the potential benefit of physically administering therapeutics directly to the intended site of action. However, local administration of nanoparticles through alternative routes does not always restrict targeting to the initial site of delivery. When subcutaneously injected, nanoparticles with a diameter of <100 nm are prone to clearance by lymphatic vessels, whereas larger nanoparticles are generally retained in the interstitial space near the site of injection 35, 36 . As such, subcutaneous injection of particles with a diameter of <100 nm can be a method for targeted delivery to
Box 1 | Classes of polymeric nanoparticles
• Solid nanoparticles comprise a dense polymer matrix that is typically stabilized by hydrophobic interactions of the constituent polymer or polymers. A key advantage of these systems is that they enable the controlled release of various cargo, ranging from hydrophobic small molecules to large proteins. An example of such a solid nanoparticle is BIND-014, which is a solid poly(DL-lactide) (PLA) nanoparticle formulation that is synthesized using an emulsion solvent evaporation process. These docetaxel-loaded nanoparticles are coated with both polyethylene glycol (PEG) and prostate-specific membrane antigen-targeting ligands. BIND-014 is currently in clinical trials for the treatment of prostate and lung cancer 8 .
• Micelles are composed of amphiphilic components that are organized by the hydrophobic effect such that they have a distinct lipophilic core and hydrophilic outer layer. In these systems, the drug cargo is typically limited to hydrophobic molecules that are entrapped in the core.
An example of such a micelle is Genexol-PM, which is composed of a PEG-PLA block co-polymer loaded with paclitaxel, and has been investigated in clinical trials for breast, pancreatic, lung and ovarian cancer 105 .
• Dendrimers are branched, tree-like structures that enable excellent control over size, dispersity and functionalization during synthesis. Various types of drug cargo can be made to associate with the branched polymer matrix or attach to the dendrimer surface. An example of a dendrimer is SPL7013, which is a lysine-based dendrimer with antimicrobial properties that is being evaluated for the prevention of HIV, genital herpes and human papillomavirus infection 106 .
• Polyplexes are self-assembled nanoparticles that are stabilized by hydrophobic or electrostatic interactions with the constituent polymer or polymers and the drug cargo. An example of a polyplex is CALAA-01, which is a polyplex of PEGylated cyclodextrin loaded with small interfering RNA (to knock down the M2 subunit of ribonucleotide reductase) and coated with transferrin. CALAA-01 has been in clinical trials for the treatment of solid tumours 9 . Similarly, CRLX101 is a polyplex of PEGylated cyclodextrin conjugated to camptothecin that has been evaluated in clinical trials for renal, ovarian, and rectal cancer 107 .
surrounding lymph nodes [37] [38] [39] [40] , provided that the particles are not so small that they leak into blood capillaries 35 . Although targeting the lymphatic system by subcutaneous administration of nanoparticles with a diameter of <100 nm can be inefficient 41 , this approach nevertheless has potential for the development of DNA-based vaccines 42 and in the treatment of certain lymphomas 43 .
Mucosal delivery. Mucosal administration offers the advantages of local tissue targeting [44] [45] [46] while also providing potential routes for sustained systemic administration that are less invasive than intravenous injection [47] [48] [49] . Mucus provides a protective barrier on the epithelia of numerous tracts and structures in the body that are potential administration routes for nanotherapeutics. For example, topical vaginal administration of polymeric nanoparticles enables targeted delivery to the vaginal epithelium, and can be used to deliver siRNA 50,51 and drugs 52, 53 to prevent and treat infectious diseases 51, 54 or cancer 55, 56 . Molecular engineering of these systems circumvents obstacles to local drug action; in particular, design of the nanoparticle surface enables particles to penetrate cervical mucus and to reach the underlying epithelium 50, 57, 58 . For example, the addition of PEG to the nanoparticle surface enhances mucus penetration 58, 59 , which can also be improved by modulating nanoparticle size and attraction to mucin fibres 60, 61, 62 . Other molecules attached to the surface of nanoparticles, such as chitosan, can disrupt tight junctions and increase epithelial penetration 63 , which provides a tool for controlling nanoparticle targeting after topical delivery to the vagina, the bladder and other mucosal epithelial sites 64, 65 . Alternatively, another approach for mucosal delivery is to improve mucus adhesion 66 or binding 67 , which then limits penetration to the epithelium, enables topical release of drug payloads and links nanoparticle clearance to the natural clearance of mucus.
Regardless of the specific route of delivery, a consistent theme in the preceding examples is the need to carefully consider how the molecular properties of the delivered nanoparticles -such as shape, size, charge and chemical character -will guide their interactions with the local environment after delivery. Different aspects of targeting -even those that seemingly operate on considerably different scales (that is, macroscopic versus microscopic) -are nonetheless highly interdependent. Consequently, overcoming the obstacles associated with targeting requires moving beyond the optimization of individual elements of targeting to instead focus on how all aspects work simultaneously. In the following sections, we introduce molecular aspects of targeted delivery and discuss specific issues that need to be addressed to ensure that molecular-targeting strategies can be reliably incorporated within this holistic approach.
Molecular targeting
Given the potential for high affinity and specificity in conjugating a native ligand or relevant antibody to nanoparticles, it is understandable that much attention in the field has been focused on these moleculartargeting approaches. However, it is becoming clear that the highly specific targeting capabilities that are associated with molecules such as antibodies cannot simply be grafted on to the therapeutic functionality of a drugloaded nanoparticle. Indeed, the conjugation of targeting molecules to the surface of nanoparticles can impair the bioactivity of the targeting molecule 12 , as well as negatively affect the therapeutic efficacy of a nanoparticle by reducing passive targeting by enhanced immune elimination 13 . Moreover, the addition of targeting ligands does not substantially alter the biodistribution of systemically administered nanoparticles 5, 68, 69 . Despite these challenges, active targeting can still have a role as part of the broader toolkit of targeted drug delivery, particularly when the route of administration ensures that the conjugated ligand will find its intended receptor. However, issues that can affect both specificity and therapeutic efficacy must be addressed to achieve success with molecular-targeting strategies (TABLE 3) .
Targeting specificity challenges. Most polymeric nanoparticle formulations are taken up -at least to some extent -by many different types of cells, even in the absence of modifications that are intended to enhance nanoparticle internalization 70, 71 . Although an inherent propensity for cellular uptake can be therapeutically beneficial, it nevertheless provides an impediment to specific targeting by reducing the ability to regulate unintended particle uptake. Cellular uptake can be sensitive to the physical characteristics of the nanoparticles -including properties such as particle shape, size, charge and hydrophobicity [71] [72] [73] [74] [75] -thereby providing a potential means for controlling the level of uptake in the absence of a specific targeting ligand. However, without a singular mechanism linking the properties of the particle to cellular uptake, it is difficult to predict what combination of properties will be most relevant for a given nanoparticle formulation and cellular target. Moreover, uptake observed for one cell in one environment may not occur for all cells in all environments, which makes it risky to extrapolate from in vitro single-cell culture models to in vivo conditions. Nevertheless, coating the surface of polymeric nanoparticles with inert molecules -such as PEG 76 or hyper-branched polyglycerol 77 -can substantially reduce unwanted cellular interactions both in vivo and in vitro.
Many studies have focused on understanding the basic mechanisms underlying this intrinsic ability of nanoparticles to be taken up by cells 71 . In some cases, this nonspecific particle uptake may be attributable to the electrostatic properties of the particles; for example, cationic particles associate with cells on the basis of ionic interactions with anionic cell membranes and cell-surface components leading to enhanced particle uptake 78 . But perhaps more importantly (especially in vivo), there is now substantial evidence indicating that surface-adsorbed serum or plasma proteins are crucial determinants of cell-nanoparticle interactions 12, 79, 80 . These adsorbed proteins, often referred to as a protein corona, can rapidly (within seconds) associate with nanoparticles following exposure to serum-containing medium or blood. Using a mass spectrometry-based approach, polystyrene nanoparticles were shown to associate with hundreds of different serum proteins; whether the specific proteins adsorbed depended on the charge, size and chemical composition of the nanoparticle 79 . Notably, the ability of surface-conjugated molecules (such as transferrin) to provide specific nanoparticle targeting was repressed by the presence of the protein corona 12 .
Moreover, many of the serum proteins that adsorb to nanoparticle surfaces may themselves activate receptor-mediated endocytosis 16 . Consequently, what is observed as a non-specific effect may actually result from an unintended, specific interactions between nanoparticles and the biological milieu.
Thus, whether by inhibiting the biological activity of a targeting ligand or by providing alternative, unintended routes of cellular uptake, proteins that are adsorbed from either the circulation or the local tissue environment can interfere with active targeting. This role of serum proteins on drug targeting extends beyond the field of nanoparticles: binding to albumin can prevent renal filtration of macromolecular drugs 81 and certain lipoproteins can direct the tissue accumulation and cellular uptake of various nucleic acid therapeutics 82 . These other fields have adapted to exploit drug interactions with serum components. Similarly, improved means for either controlling the composition of the nanoparticle protein corona or minimizing its effects must be developed 80, 83 . Such strategies should focus not only on reducing uptake by phagocytic cells of the immune system (as is often the motivation with surface PEGylation), but also on preserving targeting specificity. Finally, it will be important to better understand how the protein corona varies with the physicochemical properties of a given particle and with different anatomical routes of administration 80 . The ability to generate specific antibodies against any cell-surface receptor would seem to suggest a wide palette of potential targets from which to choose. However, the vast majority of these molecules are not unique to a single population of cells, which severely restricts the number of cell-surface receptors that are useful for targeting purposes. As a result, numerous studies have focused on just a few specific targets that are typically overexpressed on cancer cells (for example, ERBB2 (also known as HER2) and the transferrin receptor) 5 . Expanding the list of potential targets for a given pathology necessarily requires a thorough understanding of the fundamental biology underlying the disease. It is also essential to consider surface expression levels of the target receptor on intended versus non-intended cellular targets, particularly within the context of a given nanoparticle avidity. In instances for which a suitable cell-surface target does exist, it is also important to realize that the binding of the targeting moiety to the targeted receptor may itself lead to a biological response that can either enhance or inhibit the desired therapeutic effect 84 . Therapeutic efficacy challenges. Even if a nanoparticle can successfully navigate the above-mentioned pitfalls and be specifically taken up in to a targeted cell, this does not guarantee therapeutic efficacy. The intracellular fate of nanoparticles and the timing of agent release determine whether the active agent will 'find' its intended site of action. CNS, central nervous system; MPS, mononuclear phagocyte system. *Indicates that there is currently an incomplete understanding and that more research is required.
A canonical example of this challenge is in the delivery of siRNA to the cytosol 85 . The therapeutic potential of siRNA is far-reaching, with the possibility to have an impact on diverse disease states (such as chronic inflammatory disorders, neurodegenerative disorders, viral infections, organ transplant rejection and cancer 86 ) with high target specificity. To be effective, siRNA molecules need to reach the endogenous processing machinery in the cytosol, which is a difficult challenge given the instability and short half-life of extracellular siRNA. Various nanoparticle formulations have been engineered to successfully protect siRNA from degradation, but many of these formulations become trapped in endosomal compartments and/or they are trafficked to lysosomes where the particle and siRNA are ultimately degraded without ever reaching their target 87 . To combat this, substantial effort has been focused on facilitating endosomal escape by adding drugs 88 , cationic polymers 89 , lipids 90 or fusogenic peptides 91 to the nanoparticle formulation. Enhancing siRNA delivery by endosomal escape is just one example of controlling the fate of nanoparticles in cells; there is a diverse array of molecular modifications that can aid in regulating intracellular delivery and localization 92 . For example, cell-penetrating peptides are a widely used nanoparticle modification to improve cellular uptake and to modulate intracellular fate; however, the functional mechanisms of many cell-penetrating peptides (let alone those attached to nanoscale structures) remain unclear 93 . Gaps in the understanding of activity and mechanism of action (as well as potential for toxicity) indicate that the use of molecular modifications should be cautiously considered, thus providing another illustration of how each aspect of molecular composition must be evaluated as an element in a holistic design.
Achieving cellular specificity through active targeting remains the non-trivial goal of many nanomedicines. Active targeting is confounded by various factors, including nanoparticle physicochemical properties, interactions specific to the route of delivery and challenges that are unique to the agent being delivered, for example, cytosolic delivery of siRNA. To further complicate this issue, some efficacious actively targeted nanoparticles have only a narrow window in which the targeting capacity of a conjugated ligand will be retained 94 . Consequently, it cannot be assumed that any given disease or nanoparticle platform will be compatible with active targeting approaches. This fact reinforces the argument that active molecular targeting should not be viewed as the only approach for targeting disease. Rather, ligand conjugation is appropriate only when the route of delivery can transport the nanoparticle to the cell that displays the targeted receptor of interest without compromising the therapeutic efficacy of the delivered drug. Moreover, the intracellular fate of the nanoparticle after uptake needs to support effective therapeutic delivery. These requirements will not be present in all clinical settings or for all agents. By strictly biasing the use of molecular-targeting strategies to diseases and treatment modalities that meet these criteria, we will substantially improve the odds of successfully incorporating molecular targeting into therapeutic design.
Temporal targeting
In addition to selecting the administration route and controlling the aforementioned molecular characteristics, nanoparticle targeting can be further improved from a temporal perspective. Temporal targeting exploits therapeutic windows to maximize drug delivery; for example, the lungs have a larger window of therapeutic opportunity for systemically administered agents than the spleen. The times required for the lungs and spleen to receive a volume equivalent to the total blood volume in humans are approximately 1 minute and 64 minutes, respectively 16 . In the context of nanoparticle therapeutics, temporal targeting can be achieved through an understanding of disease progression and pharmacokinetics, as well as through the engineering of nanoparticles that impart control over when a drug is delivered.
Biological timing. Disease pathophysiology can substantially impair or improve the amenability to nanoparticle treatment. Developing targeted nanomedicines with a disease-first approach requires a detailed understanding of pathophysiology because treatment susceptibility for diseases often lessens with time. Typically, treating disease at early stages will prevent further spread and pathogenesis, but early treatment may also be advantageous from a pharmacokinetic perspective. For example, in cancer, elevated tumour interstitial fluid pressure results from a combination of poorly formed vasculature and a lack of functional lymphatic drainage, which in turn reduces the convective flow of nanoparticles into the tumour parenchyma 95 . As tumours grow, the interstitial fluid pressure typically intensifies and further impedes nanoparticle transport 96 . Thus, tumour delivery of nanoparticles can be improved through temporal targeting of early-stage tumours (FIG. 2a) . Similarly, cystic fibrosis involves the thickening of the mucus lining the airways and intestinal tract, which can increase the mucosal barrier and impede delivery of nanotherapeutics 97 . Although nanoparticles with muco-adhesive and muco-penetrating properties have been engineered to exploit and overcome mucus retention 62, 67, 98, 99 , early treatment of cystic fibrosis may circumvent this obstacle (FIG. 2b) . Note that in addition to the temporal aspects of disease pathology, other aspects of biological timing can influence therapeutic windows. For example, the cycling of the female reproductive mucosa can affect the timing for administration of intravaginal or intrauterine therapies. Similarly, the cycle of expansion and contraction of the bladder influences tissue structure in the bladder wall and therefore also influences tissue permeability to nanoparticles. Designing nanomedicines that target specific therapeutic windows for a given disease may be limited in some cases by an incomplete understanding of disease pathogenesis. Preclinical models can be predictive, but not necessarily representative, of disease progression in humans. For example, the enhanced permeability and retention effect observed in many preclinical models may be less prevalent in human tumours 100 . A key benefit of nanoparticle platforms is their amenability to deliver a diverse array of cargos. Thus, multifunctional nanoparticles can combine therapy with imaging modalities (termed theranostics 101 ) to help identify times when a given disease is most suscept ible to treatment. A common example of a theranostic is the fabrication of nano particles that are loaded with a chemotherapeutic and are functionalized with an imaging contrast agent 102 . However, similar to the concerns with molecular targeting, the added complexity of theranostic nanosystems suggests that a careful approach is required.
Controlled release. In addition to the capacity for multifunctional properties, another property of polymeric nanoparticles is the ability to protect drug cargo from the time of administration to delivery at the intended tissue, cell or intracellular location, and to release it in a sustained manner. Given the numerous physiological and cellular barriers facing the delivery of nanotherapeutics, control over when to release an encapsulated drug can substantially affect therapeutic efficacy. In contrast to other classes of nanocarriers, most polymeric nanoparticle systems can be tuned to yield desirable release kinetics. This process -known as controlled release -is typically achieved by regulating the rates of polymer biodegradation and drug diffusion outwards through the polymer matrix. As such, polymeric nanosystems have been developed with release durations ranging from minutes to weeks 103 . In particular, biodegradable poly(ester) polymers, such as PLA and PLGA, are well known for their use in formulating controlled release nanoparticles. A primary goal in developing these systems is to align drug release profiles with nanoparticle pharmacokinetics. For example, the drug release profiles of various PLA nanoparticles (with similar compositions to BIND-014) were tuned to release over several days to capitalize on the extended systemic circulation time of the PEGylated nanocarriers, which ultimately accumulated in tumours 8 . In another example, PLGA nano particles that are administered intranasally to a mouse model of cystic fibrosis resided within diseased lungs and achieved pharmacological effects through sustained drug release for up to 11 days 19 .
Another approach to controlling drug release is the development of modular nanoparticles in which delivery of the payload is triggered. For example, a polymeric nanoparticle system was designed to sequentially deliver an anti-angiogenesis agent followed by a chemotherapy agent 104 . This approach triggered vascular shutdown and entrapped the nanoparticles within a tumour before releasing the chemotherapeutic, thereby temporally targeting drug release to coincide with the time at which a disease was susceptible to treatment. With the ability to respond when needed, modular nanosystems may be paradoxically simpler than other complex molecularly targeted nanoparticles. Through the coordinated alignment of pharmacokinetics and drug delivery with therapeutic windows that are provided by disease pathophysiology, polymeric nanoparticles present a unique technology for the temporal targeting of disease that has not yet been fully exploited.
Conclusion
Polymeric nanoparticles can be synthesized with control over particle composition, incorporation of many types of drug agents with tuneable release kinetics and presentation of targeting ligands. However, the effective use of these nanomaterials for targeted treatment of human disease remains limited. We believe that effective targeting requires a careful consideration of multiple length scales: from macroscopic to microscopic. Here, we have presented a holistic approach to nanoparticle design, which benefits from the considerable progress that has been made over the past decade. This new approach, which encompasses the route of administration, molecular composition of the nanocarrier and temporal coordination, requires that nanoparticle design be directed by pathophysiology and be integrated across all of these elements. This holistic perspective has already been applied in some settings; for example, the aforementioned local delivery of nanoparticles for controlled drug release in the brain engages all of these targeting elements. In addition, these principles are not mutually exclusive; for example, molecular modifications and drug release kinetics should be tuned for a given nanoparticle administration route. We propose that judicious application of this holistic approach will substantially reduce the hurdles in developing polymeric nanoparticles for the effective treatment of cancer and many other intractable diseases. Notably, the holistic view that we have outlined here is not fully inclusive; in the emerging era of personalized medicine, drugs are being tailored for specific individuals and disease indications. Thus, drugs themselves can impart another layer of targeting. Ultimately, the definition of different aspects of targeting does not matter as much as the approach taken to achieve targeting, which we believe should consider every possible tool in the arsenal to achieve the desired therapeutic end.
Correction
In Box 1 on page 241, BIND-014 was described as being loaded with doxorubicin, when it is in fact loaded with docetaxel, as described in Table 1 on page 242. This has been corrected in the online version.
